{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:02:03Z","timestamp":1789563723495,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41581-026-01116-7","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:56:15Z","timestamp":1786622175000},"page":"673-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leave no one behind: optimizing kidney protection in type 1 diabetes"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1116_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112277","volume":"225","author":"GD Ogle","year":"2025","unstructured":"Ogle, G. D. et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International Diabetes Federation Atlas, 11th edition, and the T1D Index version 3.0. Diabetes Res. Clin. Pract. 225, 112277 (2025).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1116_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/dc20-2839","volume":"44","author":"R Krist\u00f3fi","year":"2021","unstructured":"Krist\u00f3fi, R. et al. Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study. Diabetes Care 44, 1211\u20131218 (2021).","journal-title":"Diabetes Care"},{"key":"1116_CR3","volume":"47","author":"KR Tuttle","year":"2025","unstructured":"Tuttle, K. R. et al. Prevalence and severity of chronic kidney disease in a population with type 1 diabetes from a United States health system: a real-world cohort study. Lancet Reg. Health Am. 47, 101130 (2025).","journal-title":"Lancet Reg. Health Am."},{"key":"1116_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001071","author":"B Carstensen","year":"2020","unstructured":"Carstensen, B., R\u00f8nn, P. F. & J\u00f8rgensen, M. E. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996\u20132016. BMJ Open Diabetes Res. Care https:\/\/doi.org\/10.1136\/bmjdrc-2019-001071 (2020).","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"1116_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","volume":"46","author":"SC Naaman","year":"2023","unstructured":"Naaman, S. C. & Bakris, G. L. Diabetic nephropathy: update on pillars of therapy slowing progression. Diabetes Care 46, 1574\u20131586 (2023).","journal-title":"Diabetes Care"},{"key":"1116_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal, R. et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N. Engl. J. Med. 393, 533\u2013543 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1116_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","volume":"11","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol. 11, 536\u2013540 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1116_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1681\/ASN.0000000540","volume":"36","author":"VS Sridhar","year":"2025","unstructured":"Sridhar, V. S. et al. Efficacy and safety of sotagliflozin in patients with type 1 diabetes and CKD. J. Am. Soc. Nephrol. 36, 890\u2013900 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1116_CR9","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2337\/dc19-0937","volume":"42","author":"DH van Raalte","year":"2019","unstructured":"van Raalte, D. H. et al. The Impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes. Diabetes Care 42, 1921\u20131929 (2019).","journal-title":"Diabetes Care"},{"key":"1116_CR10","doi-asserted-by":"publisher","unstructured":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 12, 51\u201360 https:\/\/doi.org\/10.1016\/s2213-8587(23)00322-4 (2024).","DOI":"10.1016\/s2213-8587(23)00322-4"},{"key":"1116_CR11","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1038\/s41591-026-04274-0","volume":"32","author":"Y Xu","year":"2026","unstructured":"Xu, Y. et al. Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes. Nat. Med. 32, 1682\u20131685 (2026).","journal-title":"Nat. Med."},{"key":"1116_CR12","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1111\/dom.70640","volume":"28","author":"ML Caramori","year":"2026","unstructured":"Caramori, M. L., Repetto, E., Perkins, C., Pandey, A. & Rossing, P. Cardio-kidney-metabolic therapy use among adults with type 1 diabetes and chronic kidney disease. Diabetes Obes. Metab. 28, 4344\u20134351 (2026).","journal-title":"Diabetes Obes. Metab."},{"key":"1116_CR13","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.7326\/M23-1023","volume":"176","author":"R Agarwal","year":"2023","unstructured":"Agarwal, R. et al. Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes : a mediation analysis. Ann. Intern. Med. 176, 1606\u20131616 (2023).","journal-title":"Ann. Intern. Med."},{"key":"1116_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa2512854","volume":"394","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink, H. J. L. et al. Finerenone in type 1 diabetes and chronic kidney disease. N. Engl. J. Med. 394, 947\u2013957 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1116_CR15","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1111\/dom.16606","volume":"27","author":"EB Stougaard","year":"2025","unstructured":"Stougaard, E. B. et al. The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study. Diabetes Obes. Metab. 27, 5432\u20135443 (2025).","journal-title":"Diabetes Obes. Metab."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01116-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01116-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01116-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:34Z","timestamp":1789560154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01116-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1116"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01116-7","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"13 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.R. has received consultancy and\/or speaking fees (honoraria paid to Steno Diabetes Center Copenhagen) from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Roche and Regeneron; research grants from AstraZeneca, Bayer, Lexicon Pharmaceuticals and Novo Nordisk; and study drugs for investigator-initiated studies from Bayer, Novo Nordisk and Lexicon Pharmaceuticals. H.J.L.H. has received honoraria paid to employer University of Groningen; received grants from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen and Novo Nordisk; received consulting fees from AstraZeneca Alexion, Alnylam, Amgen, Bayer, Boehringer Ingelheim, Biocity Biopharmaceuticals, Dimerix, Eli Lilly, Novo Nordisk, Novartis, Otsuka, Roche and Travere Therapeutics; received speaker fees from AstraZeneca, Bayer and Novo Nordisk; and received support for attending meetings and\/or travel from AstraZeneca and Eli Lilly.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}